Your AI-Trained Oncology Knowledge Connection!
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the treatment landscape of recurrent head and neck cancer.
In the old days, not too long ago, doctors’ offices were full of paper records, which filled shelf after shelf. This cumbersome form of keeping track of patients was effective in its own way, but with the rise of modern medicine and the power of computing, there is a need to move beyond.
As oncologists await the next major treatment advances in metastatic castration-resistant prostate cancer (mCRPC), the key in the interim is to optimize the available therapies, says Robert Dreicer, MD.
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.
Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.
As immunotherapy continues to make headway in several different cancer types, these agents are only just arriving to the treatment landscape of head and neck cancer.
Treatment in lung cancer continues to evolve at a rapid pace with the arrival of a set of efficacious new agents and promising evidence-based data. According to Corey J. Langer, MD, a veritable avalanche of additional data is on the way.
Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.
The expression of PD-L1 has been at the forefront of biomarker development for PD-1/PD-L1 inhibitors, but there is much uncertainty surrounding its use and other biomarkers are needed.
Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses the use of PD-L1 as a biomarker in treating patients with lung cancer.
Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.
Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses recent advancements in cervical cancer.
Findings from a highly anticipated, randomized, phase II trial could possibly pave the path for the FDA approval of the first targeted therapy for patients with triple-negative breast cancer, explains Linda T. Vahdat, MD.
PARP inhibition is quickly becoming a major element of the overall ovarian cancer treatment landscape, as several of these agents are continuing to advance through clinical development.
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the FDA approvals of the PD-L1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.
Nivolumab (Opdivo) may be the only checkpoint inhibitor that is approved by the FDA as a treatment of patients with Hodgkin lymphoma, but other immunotherapies—alone and in combination with other novel agents—are emerging in other indications.
Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the potential of combination regimens involving radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).
As a treatment of patients with advanced ovarian cancer, evidence has shown that neoadjuvant chemotherapy has reduced mortality and improved quality of life. However, oncologists are still challenged at how to deploy this treatment approach in clinical practice.
Impactful clinical trial data that have led to approvals of novel agents and regimens over the last few years has led to a significant transformation in the multiple myeloma landscape.
Using combination regimens in an effective manner will likely be a go-to method with immunotherapy in multiple myeloma, in an effort to induce durable responses in patients.
John L. Marshall, MD, chief, Division of Hematology/Oncology, Georgetown University Hospital, discusses potential obstacles ahead with the Cancer Moonshot Initiative following the results of the 2016 United States presidential election.
Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the current status of immune targeting as potential treatment for patients with ovarian cancer.
Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses evolving treatment strategies for patients with colorectal cancer, with regards to molecular features such as sidedness.
Michael J. Mauro, MD, hematologist, leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses how to best select therapies for patients with chronic myeloid leukemia.
Barbara A. Burtness, MD, professor of Medicine (Medical Oncology), clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses emerging immunotherapies and ongoing clinical trials in head and neck cancer.
Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses the lenvatinib trial.
Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).
Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.
